In the Margins

Sequoia Fund's Valeant bet highlights concentration risks

November 2, 2015

By The Wall Street Journal

Concentrated bets on individual stocks raise issues for mutual funds and their investors—a matter highlighted last week at Sequoia Fund, one of the biggest investors in controversial drug maker Valeant Pharmaceuticals International Inc. Placing outsize bets on well-chosen stocks can lead to strong performance, but concentration increases the riskiness of a fund and raises questions about how much is too much. Read the original story from The Wall Street Journal.

 

 

Most Read

Top of the Agenda - Governance
Q&A: Back to the future of work

Now that summer is officially here, folks are beginning to look forward to the fall and wondering when (or if) things will go back to some ...

Top of the Agenda - Regulatory
In-person voting relief extended through year-end

Mutual fund boards can continue conducting business—including voting on contract approvals and renewals and other important matters—virtually through the end of 2020, according to the Securities ...